Gyre Therapeutics, Inc. (GYRE) Stock Forecast
GYRE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $18.67 average of analyst targets
- Upside to target
- +207.0% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-0.14
- 52-week range
- $5.56 – $8.76
GYRE analyst ratings
3 analystsNumber of analysts at each rating.
GYRE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GYRE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.19 | −$0.06 | $0.03 | −488.9% | 3 |
| Current fiscal year (2026) | −$0.40 | −$0.61 | −$0.22 | $0.02 | −2,100.0% | 3 |
| Next fiscal year (2027) | −$0.23 | −$0.47 | $0.00 | −$0.40 | +41.2% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GYRE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $28.4M | $28.0M | $28.8M | −7.1% | 3 |
| Current fiscal year (2026) | $109.5M | $108.9M | $110.0M | −6.1% | 3 |
| Next fiscal year (2027) | $139.6M | $120.0M | $159.2M | +27.5% | 2 |
GYRE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GYRE revenue: reported and forecast
GYRE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.07 | −$0.07 | −$0.07 | −$0.12 | +59.2% | 1 up · 2 down |
| Current fiscal year (2026) | −$0.29 | −$0.29 | −$0.29 | −$0.29 | −$0.40 | +37.9% | 1 up · 2 down |
| Next fiscal year (2027) | −$0.12 | −$0.12 | −$0.12 | −$0.12 | −$0.23 | +104.3% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GYRE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GYRE beat in 3 of 9.
What analysts expect from GYRE
3 analysts cover Gyre Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.67, 207.0% above the latest close of $6.08. Analysts expect earnings of −$0.40 per share for 2026, −2,100.0% from a year earlier. For 2027 the average estimate is −$0.23 per share on revenue of $139.6 million. Gyre Therapeutics beat the EPS estimate in 3 of the last 9 quarters.
Related: GYRE income statement, GYRE key metrics, GYRE chart. See the GYRE stock overview for the latest quote and news.
GYRE forecast FAQ
What is Gyre Therapeutics's price target?
The average analyst price target for Gyre Therapeutics is $18.67, 207.0% above the latest close of $6.08.
Is Gyre Therapeutics a buy, hold or sell?
Of 3 analysts covering Gyre Therapeutics, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Gyre Therapeutics's EPS forecast?
Analysts forecast −$0.40 per share for 2026 (range −$0.61 to −$0.22); for 2027 the estimate is −$0.23.
What is Gyre Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $109.5 million, growth of −6.1%; for 2027 it is $139.6 million.
When does Gyre Therapeutics report earnings?
Gyre Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 6, 2026; the EPS estimate is $-0.14.
Does Gyre Therapeutics usually beat earnings estimates?
Gyre Therapeutics reported EPS at or above the analyst estimate in 3 of the last 9 quarters.